BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 207 filers reported holding BLUEBIRD BIO INC in Q3 2016. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $311 | +238.0% | 97,743 | +636.7% | 0.03% | +181.8% |
| Q4 2022 | $92 | -100.0% | 13,268 | -91.2% | 0.01% | -91.3% |
| Q3 2022 | $959,000 | +899.0% | 151,570 | +666.9% | 0.13% | +876.9% |
| Q1 2022 | $96,000 | -75.4% | 19,764 | +62.1% | 0.01% | -70.5% |
| Q2 2021 | $390,000 | -85.6% | 12,190 | -86.5% | 0.04% | -90.2% |
| Q1 2021 | $2,714,000 | +816.9% | 90,000 | +1295.3% | 0.45% | +508.1% |
| Q1 2020 | $296,000 | -91.5% | 6,450 | -68.4% | 0.07% | -59.8% |
| Q1 2018 | $3,485,000 | +1395.7% | 20,409 | +493.6% | 0.18% | +1315.4% |
| Q3 2016 | $233,000 | -95.3% | 3,438 | -94.1% | 0.01% | -94.7% |
| Q3 2015 | $4,996,000 | -12.4% | 58,401 | +72.4% | 0.25% | +12.3% |
| Q2 2015 | $5,704,000 | +349.8% | 33,880 | +222.7% | 0.22% | +338.0% |
| Q1 2015 | $1,268,000 | -32.6% | 10,500 | -48.8% | 0.05% | -61.8% |
| Q4 2014 | $1,880,000 | +296.6% | 20,500 | +55.3% | 0.13% | +424.0% |
| Q3 2014 | $474,000 | – | 13,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
| qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
| Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
| Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
| Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
| HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
| Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
| PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
| Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
| Summit X, LLC | 103,424 | $651,000 | 0.19% |